Akebia Therapeutics
We're focused on the development & commercialization of therapeutics for people living with kidney disease.
Cambridge, United States
268 employees
Post Ipo Debt
Total: $442.50M
Biotechnology, Health Care +1
General Information
Get notified when Akebia Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Akebia Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Akebia Therapeutics
Taxonomy: biopharmaceutical company, therapeutics, kidney disease, pharmaceutical development, commercialization, medical research, drug development, Cambridge, Massachusetts
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | •••••• | 1 |
|
30 Jan 2024 |
| Post-IPO Equity | •••••• | - | 11 May 2020 | |
| Post-IPO Debt | •••••• | 1 | •••• •••• | 12 Nov 2019 |
| Private Equity Round | •••••• | - | 22 Apr 2015 | |
| Series C | •••••• | 9 |
|
04 Jun 2013 |
Akebia Therapeutics Alternatives & Competitors
Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and de...
Developing curative genome editing treatments
Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central ne...
FAQ About Akebia Therapeutics
Don't just browse. Track.
Signal Tracker monitors Akebia Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
